← board
ELAB
distress 6/10 · elevated risk$0.93-9%today-100% from 52w high
Revenue
pre-revenue
Liquidity
$15M
Runway
2.0 yrs
Shares 1y
+206%
Price & events
-95.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-8.5%
1D
-14.4%
1W
-29.3%
1M
-68.3%
3M
-95.6%
6M
-99.5%
1Y
-100.0%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $4.24M
- Volume
- 317.50K
- 52 Week Range
- $0.93 – $217
- Total Shares
- 4.54M
- Float Shares
- 4.09M
- Short %
- 7.29%
- % Held by Insiders
- 9.99%
- % Held by Institutions
- 1.57%
- RVOL
- 0.07x
- Beta
- -0.24
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-04-23partnershipExclusive option agreement for U.S. Patent No. 12,277,716 B2 covering autonomous navigation in GPS-denied environmentsSEC 8-K
- 2026-04-21partnershipLong-term agreement to supply mission-critical aerospace and defense components to Turbo-Jet Products Co., Inc.SEC 8-K
- 2026-04-09partnershipAGA Precision Systems executed a long-term agreement with a globally recognized Tier 1 aerospace and defense company to supply precision CNC-manufactured components.SEC 8-K
- 2026-04-06partnershipExclusive option agreement to license patent for multi-domain drone payload technologySEC 8-K
- 2026-03-31partnershipLong-term agreement to supply mission-critical aerospace and defense components to Turbo-Jet Products.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.